Clinical Trials Logo

GBA Gene Mutation clinical trials

View clinical trials related to GBA Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05287503 Active, not recruiting - Parkinson Disease Clinical Trials

Ambroxol as a Disease-modifying Treatment in GBA-PD

AMBITIOUS
Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463). Participants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.